Category: Articoli recensiti

Apri l’email ricevuta da notifica-eligo@evoting.it  Clicca sul link presente in basso nell’email Inserisci le credenziali Clicca su “Guarda videoconferenza” (NON CHIUDERE LA PAGINA di ELIGO!) Inserisci nome, cognome, email Autorizzare

Apri l’email ricevuta da notifica-eligo@evoting.it  Clicca sul link presente in basso nell’email Inserisci le credenziali Clicca su “Guarda videoconferenza” (NON CHIUDERE LA PAGINA di ELIGO!) Inserisci nome, cognome, email Autorizzare

Objective: To investigate the characteristics and predictive roles of lymphocyte subsets in COVID-19 patients. Method: We evaluated lymphocyte subsets and other clinical features of COVID-19 patients and analysed their potential

Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of

Various comorbidities represent risk factors for severe coronavirus disease 2019 (COVID-19). The impact of smoking on COVID-19 severity has been previously reported in several meta-analyses limited by small sample sizes

Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all

Background: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. Methods: We conducted

Italy was one of the most affected nations by coronavirus disease 2019 outside China. The infections, initially limited to Northern Italy, spread to all other Italian regions. This study aims

Italy was one of the most affected nations by coronavirus disease 2019 outside China. The infections, initially limited to Northern Italy, spread to all other Italian regions. This study aims

Objective: This observational study aimed to determine optimal timing of interleukin-6 receptor inhibitors (IL6ri) administration for Coronavirus disease 2019 (Covid-19). Methods: Patients with Covid-19 were given an IL6ri (sarilumab or